Title:
抗精神病薬及びその用途
Document Type and Number:
Japanese Patent JP7377548
Kind Code:
B2
Abstract:
An object of the present invention is to provide a novel therapeutic agent for a mental disorder with abnormal neurodevelopment as a pathological condition. The present invention provides an antipsychotic drug containing a Rho kinase inhibitor as an active ingredient. The antipsychotic drug can be used, for example, in the treatment of schizophrenia, autism spectrum disorder, bipolar disorder, or depression.
Inventors:
Norio Ozaki
Kiyofumi Yamada
Taku Nagai
Daisuke Mori
Yuko Arioka
Shu Kushima
Kiyofumi Yamada
Taku Nagai
Daisuke Mori
Yuko Arioka
Shu Kushima
Application Number:
JP2020552954A
Publication Date:
November 10, 2023
Filing Date:
September 10, 2019
Export Citation:
Assignee:
Tokai National University Organization
International Classes:
A61K31/551; A61K31/40; A61K31/4515; A61K31/454; A61K31/496; A61K31/498; A61P25/18; A61P43/00
Domestic Patent References:
| JP2011519972A |
Other References:
GARCIA-ROJO, Gonzalo et al.,The ROCK Inhibitor Fasudil Prevents Chronic Restraint Stress-Induced Depressive-Like Behaviors and D,International Journal of Neuropsychopharmacology,2017年,Vol. 20, Issue 4,pp. 336-345,DOI: 10.1093/ijnp/pyw108
MEZIANE, Hamid et al.,Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligoph,Human Molecular Genetics,2016年,Vol. 25, No. 11,pp. 2314-2323,DOI: 10.1093/hmg/ddw102
MEZIANE, Hamid et al.,Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligoph,Human Molecular Genetics,2016年,Vol. 25, No. 11,pp. 2314-2323,DOI: 10.1093/hmg/ddw102
Attorney, Agent or Firm:
Saegusa International Patent Office